Cognitive disorder

Do one in six Indians over 59 really have a mild brain disorder, as a new study suggests?

Retrieved on: 
Thursday, February 8, 2024

A new study, published in PLOS One, suggests that the prevalence of dementia in India is higher than previously thought.

Key Points: 
  • A new study, published in PLOS One, suggests that the prevalence of dementia in India is higher than previously thought.
  • Dementia is considered a major neurocognitive disorder, while mild cognitive impairment, a common early stage of dementia, a minor neurocognitive disorder.
  • The study results showed that nearly one-sixth (17.6%) of people over 59 in India have a mild neurocognitive disorder, while 7.2% have a major neurocognitive disorder.
  • Mild cognitive impairment and dementia are commonly based on performance on cognitive tests and whether cognitive changes affect everyday activities.
  • For mild cognitive impairment, people will have mild cognitive changes, but they do not affect their everyday activities.

Shortcomings

  • Despite cognition and everyday activity being key to dementia diagnostics worldwide, they have significant shortcomings, in particular for assessments in developing countries, such as India.
  • For the current study, nearly half of their participants had either no formal education or were illiterate.
  • But what else can we do to determine if someone is either at risk or has dementia?
  • Read more:
    Playing a musical instrument or singing in a choir may boost your brain – new study


Michael Hornberger does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 21, Status: Authorised

US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights

Retrieved on: 
Tuesday, November 7, 2023

The inaugural release of Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease provides a comprehensive understanding of the current and future landscape of PD medical care, according to those who intimately manage this condition.

Key Points: 
  • The inaugural release of Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease provides a comprehensive understanding of the current and future landscape of PD medical care, according to those who intimately manage this condition.
  • Spherix recently engaged 101 US neurologists, employing a combination of quantitative survey and qualitative interview methodologies.
  • Most patients treated with carbidopa/levodopa eventually experience dyskinesias and freezing episodes, highlighting one area of unmet need in their care.
  • In addition to suboptimal symptom management approaches, neurologists report a wealth of additional unmet needs they hope innovation can address.

Regional Coordination and Public Welfare Integrate Together to Write New Chapter of CPIC 2022 Sustainable Development

Retrieved on: 
Friday, April 28, 2023

In 2022, CPIC took the initiative to carry out the important regional development strategies of the county by developing sound regional development systems and building new poles of growth in key regions.

Key Points: 
  • In 2022, CPIC took the initiative to carry out the important regional development strategies of the county by developing sound regional development systems and building new poles of growth in key regions.
  • For public welfare, CPIC donated generously to charities, thus creating a rich array of charitable brands, including CPIC Green, CPIC Blue, and CPIC Red.
  • In 2021, CPIC Blue Foundation initiated a large-scale, three-year public welfare project with the theme of "protecting the memory of us all".
  • CPIC has made outstanding contributions to China's public welfare by practicing its corporate social responsibility through practical actions.

Discovery Cove® Celebrates April as Autism Acceptance Month with Renewed Autism Center Certification

Retrieved on: 
Wednesday, March 8, 2023

ORLANDO, Fla., March 8, 2023 /PRNewswire/ -- In advance of Autism Acceptance Month (April), Discovery Cove is announcing its renewal as a Certified Autism Center™, a designation the park has proudly maintained since 2019.

Key Points: 
  • ORLANDO, Fla., March 8, 2023 /PRNewswire/ -- In advance of Autism Acceptance Month (April), Discovery Cove is announcing its renewal as a Certified Autism Center™, a designation the park has proudly maintained since 2019.
  • Discovery Cove is an inviting place for visitors, as well as ideal workplace for those with ASD.
  • IBCCES has been the leader in cognitive disorder training and certification for healthcare, education, and corporate professionals around the globe for more than 20 years.
  • Now, as an employee at Discovery Cove, O'Connor calls his position as a dolphin trainer his "dream job."

Dubai Announces Initiative to Become First Certified Autism Destination™ in Middle East North Africa Region

Retrieved on: 
Thursday, December 15, 2022

We aim to encourage all travel and entertainment facilities in Dubai to take the next step and complete the IBCCES autism certification program to help Dubai become the next Certified Autism Destination™."

Key Points: 
  • We aim to encourage all travel and entertainment facilities in Dubai to take the next step and complete the IBCCES autism certification program to help Dubai become the next Certified Autism Destination™."
  • The next step to achieve the Certified Autism Destination™ designation will require a variety of travel and entertainment locations to undergo IBCCES' Certified Autism Center™ (CAC) certification process.
  • IBCCES also created AutismTravel.com , a free online resource for parents that lists certified destinations and connects families to other resources and each other.
  • Each destination listed on the site has met the Certified Autism Center™ (CAC) requirements.

PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com

Retrieved on: 
Wednesday, December 14, 2022

Tarrytown, NY, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has launched a newly updated corporate website at www.paxmedica.com.

Key Points: 
  • Howard Weisman, Chief Executive Officer of PaxMedica, commented, “Our new website underscores our ongoing commitment to develop therapeutic advancements to treat core symptoms of autism and other potentially related disorders with intractable neurologic symptoms.
  • Key features of the refreshed website include an updated design and a more engaging interface, as well as better segmentation of the key subjects and sections.
  • For more information, please visit: www.paxmedica.com
    This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events.
  • most recent quarterly reports and other filings with the U.S. Securities and Exchange Commission.

The Universal Sphere on the Comcast Center Campus Is Named a Certified Autism Center™

Retrieved on: 
Tuesday, December 6, 2022

Comcast announced that The Universal Sphere , located in the Comcast Technology Center in Philadelphia, has further expand its accessibility offerings with the launch of a sensory-friendly experience.

Key Points: 
  • Comcast announced that The Universal Sphere , located in the Comcast Technology Center in Philadelphia, has further expand its accessibility offerings with the launch of a sensory-friendly experience.
  • View the full release here: https://www.businesswire.com/news/home/20221206005982/en/
    The Universal Sphere on the Comcast Center Campus Is Named a Certified Autism Center (Photo: Business Wire)
    The launch of the sensory-friendly experience is the latest enhancement to The Universal Spheres accessibility offerings.
  • In 2021, The Universal Sphere earned designation as a Certified Autism Center (CAC), by the International Board of Credentialing and Continuing Education Standards (IBCCES).
  • Were proud and honored to have The Universal Sphere designated as a Certified Autism Center by the IBCCES, and to launch a new sensory-friendly experience.

PaxMedica to Present at the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

Retrieved on: 
Tuesday, November 22, 2022

Zachary Rome, Chief Operating Officer of PaxMedica, is scheduled to participate in one-on-one meetings with institutional analysts and investors throughout the day.

Key Points: 
  • Zachary Rome, Chief Operating Officer of PaxMedica, is scheduled to participate in one-on-one meetings with institutional analysts and investors throughout the day.
  • The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format.
  • To schedule a one-on-one meeting with PaxMedica, you may submit your request online via the link provided upon registration.
  • To register for the conference, please visit https://www.benchmarkcompany.com/news-events/upcoming-events/the-11th-an...
    The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm.

PaxMedica, Inc. Enters Into Committed Equity Investment Agreement for up to $20 Million With Lincoln Park Capital

Retrieved on: 
Friday, November 18, 2022

TARRYTOWN, NY, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has entered into a purchase agreement and registration rights agreement (together, the “Agreement”) for up to $20 million with Lincoln Park Capital Fund, LLC ("Lincoln Park").

Key Points: 
  • Any common stock that is sold to Lincoln Park will occur at a purchase price that is determined by prevailing market prices at the time of each sale with no upper limits to the price Lincoln Park may pay to purchase the common stock.
  • The Agreement does not contain any restrictions on the use of any of the proceeds and there are no financial covenants, participation rights, rights of first refusal, or penalties.
  • The Company issued common shares to Lincoln Park as consideration for Lincoln Parks commitment to purchase the Companys common stock under the Agreement.
  • The Company intends to use the net proceeds from the sale of its common stock under the Agreement for working capital and general corporate purposes to support its growth.